Lv5
988 积分 2025-04-17 加入
The evolving landscape of drug targets
13天前
已完结
Abstract B009: Enhancing Antitumor Immune Responses: Trastuzumab Deruxtecan (T- DXd) Induces Immunogenic Cell Death and Phagocytosis, Synergizing with CD47/SIRPα Checkpoint Blockade
13天前
已关闭
Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
13天前
已完结
Structural determinants of integrin β-subunit specificity for latent TGF-β
14天前
已完结
Mechanisms and therapeutic potential of the hedgehog signaling pathway in cancer
20天前
已完结
Targeting the Hedgehog pathway in cancer
20天前
已完结
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer
1个月前
已完结
The Next Generation of Antibody Drug Conjugates
1个月前
已完结
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose
1个月前
已完结
Mechanistic modeling suggests stroma-targeting antibody-drug conjugates as an alternative to cancer-targeting in cases of heterogeneous target expression
1个月前
已完结
皖公网安备34019202002308
